XML 32 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Statements of Cash Flows (Unaudited) (USD $)
6 Months Ended
Jun. 30, 2013
Jun. 30, 2012
Cash flows from operating activities:    
Net income (loss) $ 224,754 $ (519,722)
Adjustments to reconcile net income (loss) net cash provided by (used in) operating activities:    
Depreciation expense 8,775 10,047
Amortization of patents 38,825 37,957
Amortization of debt discount 0 3,065
Common stock and options for compensation, consulting, and vendor services 383,720 204,156
Accrued interest expense on notes payable 48,639 42,276
Bad debt reversal (239,501) (78,096)
Loss on Earning on Medical Joint Venture 47,903 124,179
Changes in operating assets and liabilities:    
Decrease in accounts receivable 276,549 205,555
(Increase) Decrease in inventories (218,559) 276,157
Decrease to advance to contracts 155,070 171,975
Decrease to prepaid expenses and other current assets 115,406 44,257
Decrease in other assets   18,003
Decrease in accounts payable (830,805) (846,004)
(Decrease) Increase in accrued expenses (1,727) 197,243
Net cash provided by (used in) operating activities 8,239 (108,952)
Cash flows from investing activities:    
Investment in Education Joint Venture (50,000)  
Investment in Medical Joint Venture (47,093)  
Purchases of property and equipment (2,790) (2,611)
Payment for patents rights (16,565) (12,959)
Net cash used in investing activities (116,448) (15,570)
Cash flows from financing activities:    
Proceeds from exercise of stock options 29,600  
Proceeds from the sale of common stock 50,000 150,000
Proceeds of related party loan 50,000  
Repayment of related party loan (15,000)  
Net cash provided by financing activities 114,600 150,000
NET INCREASE IN CASH AND CASH EQUIVALENTS 6,391 25,478
Cash and cash equivalents at beginning of period 165,249 97,324
Cash and cash equivalents at end of period 171,640 121,802
Supplemental disclosure of cash flow information    
Shares issued to directors for the purchase of options 29,600  
Shares issued to directors for compensation 45,000 45,000
Shares issued to employees in lieu of cash compensation $ 23,750 $ 19,375